

P&T Motion History Quick Relief Asthma Drugs

Asthma Drugs Reviewed	Motion	Date Reviewed	Scan Update Accepted as Adequate	Reiteration of Prior Motion	Decision
<p>Inhaled Short Acting Beta 2 Agonists albuterol</p> <ul style="list-style-type: none"> • (Proair Respiclick®)* <p>levalbuterol pirbuterol</p>	<p>After considering the evidence of safety, efficacy and special populations of using short acting beta agonists for quick relief of Asthma, I move that albuterol, levalbuterol, and pirbuterol are safe and efficacious. The Washington Preferred Drug List must include a nebulizer and metered dosed formulation. No single short acting beta agonist is associated with fewer adverse events in special populations. The short acting beta agonists can be subject to therapeutic interchange in the Washington preferred drug list for the quick relief of Asthma. After considering the evidence of safety, efficacy and special populations of ipratropium and ipratropium/albuterol combination for quick relief of Asthma, I move that there is not enough evidence to add these products to the Washington Preferred Drug List for the quick relief of asthma.</p>	<p>April 18, 2018</p>	<p>Yes Figueroa Chew</p>	<p>Yes Schwilke Brown</p>	<p>Passed unanimous</p>
<p>Short Acting Anticholinergics ipratropium bromide</p>					
<p>Combination Products ipratropium bromide/ albuterol</p>					

Bold = new this update

*new drug identified in scan not eligible for inclusion on PDL.

4/19/2018